Release a current, limited result

A complete PGx report records the patient identifier and accession to prevent an identity swap; method and tested allele/copy-number scope to prevent a negative, *1, or no-call from being read as excluding untested rare, hybrid, converted, or phased variants; and the diplotype to distinguish a haplotype pair from one variant. It records the activity score and predicted phenotype so translation is not mistaken for measured enzyme activity, and it states limitations or a no-call so unresolved findings are not misread as normal.

The report also names its evidence source version/date so the interpretation remains traceable as guidance, labels, allele definitions, and laboratory validation change. Its update or reissue policy determines the local response to those changes.

For an active parent drug cleared by a CYP enzyme, reduced function can raise exposure; for a prodrug requiring activation, reduced function can lower active-metabolite formation. That pharmacology explains why phenotype is not a universal instruction: release the genotype-derived result and its boundaries, then route drug-specific action to current adopted guidance and qualified interpretation.